Live Breaking News & Updates on Lexaria Bioscience Corp Stock Exchange

Stay updated with breaking news from Lexaria bioscience corp stock exchange. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Lexaria Bioscience: Exciting Drug Delivery Technology Has Potential to Disrupt Multiple Categories; Add Long Term Shareholder Value

Lexaria Bioscience s powerful, proprietary drug delivery technology, DehydraTECH has the potential to disrupt multiple categories as the company continues to receive positive results from clinical. | June 7, 2023 ....

United States , Chris Bunka , Digital Holdings , Advisory Inc , Lexaria Bioscience , Chief Executive Officer , Investigational New Drug , Lexaria Bioscience Corp Stock Exchange , Press Release , Rom Lexx Us52886n4060 ,

Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers

DehydraTECH-CBD offers distinctive mechanistic benefits related to its growing therapeutic utility

Kelowna, BC - TheNewswire - May 23, 2023 - Lexaria Bioscience Corp. , a global innovator. | May 23, 2023 ....

United States , George Jurcic , Lexaria Bioscience Corp , Drug Administration , Exchange Commission , Company Or Lexaria , New Drug , Placebo Controlled Study , Lexaria Bioscience Corp Stock Exchange , Press Release , Lobal Lexx Us52886n4060 ,

LEXARIA BIOSCIENCE CORP. : Entry into a Material Definitive Agreement (form 8-K)

Item 1.0 Entry into a Material Definitive Agreement

Lexaria Bioscience Corp. entered into a Master Services Agreement
with InClin, Inc. for the purposes of InClin acting as
Lexaria s clinical. | May 12, 2023 ....

Inclin Inc , Lexaria Bioscience Corp , Drug Administration , Master Services Agreement , Material Definitive , Investigational New Drug , Clinical Trial Agreements , Edgar Online , Lexaria Bioscience Corp Stock Exchange , Press Release , Cting Lexx Us52886n4060 ,

Lexaria Bioscience : Material Definitive Agreement - Form 8-K

Lxrp 8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
. | May 12, 2023 ....

United States , Chris Bunka , Lexaria Bioscience Corp , Inclin Inc , Securities Exchange , Master Services Agreement , Drug Administration , Securities Exchange Act , Mccurdy Road , Zip Code , Securities Act , Exchange Act , Purchase Common Stock , Material Definitive , Investigational New Drug , Clinical Trial Agreements , Principal Executive Officer , Lexaria Bioscience Corp Stock Exchange , Press Release , Xchange Lexx Us52886n4060 ,

Lexaria Bioscience : Corporate Highlight Sheet

LEXARIA BIOSCIENCE CORP.

NASDAQ: LEXX

INVESTOR CONTACT

Phone: 250-765-6424 ext. 202. | May 1, 2023 ....

British Columbia , United States , John Docherty , Chris Bunka , Helix Biopharma Corp , Altria Corp , Securities Exchange , Drug Administration , Lexaria Pharmaceutical Corp , Lexaria Nicotine , Altria Group , Fatty Acid Oil , Lexaria Bioscience Corp , British American Tobacco , Lexaria Corp , Lexaria Hemp Corp , Bioscience Corp , Active Pharmaceutical Ingredients , New Drug , Mccurdy Road , British American , North American , Helix Biopharma , Securities Act , Securities Exchange Act , Lexaria Bioscience ,